Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-OA-10CN
- Development stage
- Unknown
- Lead developer
- Pure Green Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
**PG-OA-10CN** is a fixed-dose, water-soluble sublingual tablet formulation of the phytocannabinoids cannabidiol and cannabinol, containing 10 mg of each active ingredient per tablet. Developed by Pure Green Pharmaceuticals, it has been evaluated in a Phase 2 randomized, placebo-controlled study for moderate-to-severe chronic pain associated with knee osteoarthritis. The sponsor describes the product platform as acting through the endocannabinoid system, but has not publicly disclosed a definitive receptor-level mechanism for PG-OA-10CN.
- Other names
- cannabidiol + cannabinolCBD + CBNCBD/CBN
Beyond the preview
Go deeper on PG-OA-10CN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG-OA-10CN.